IMCR
Immunocore Holdings plc
+0.70 (+2.22%)32.29USD66.9K成交股數–市值–本益比(近四季)–股價營收比+18.3%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。外國發行人(20-F)通常只申報半年或年度,逐季會有缺。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 116M+18% | 107M+14% | 104M+30% | 104M+38% | 98.0M+39% | 93.9M+34% | 80.2M+24% | 75.4M+26% | 70.5M | 70.2M | 64.9M | 59.8M |
| 營業成本 | 1.1M | 434K | 2.7M | 513K | 1.0M | 831K | 448K | 1.7M | 246K | 199K | 276K | 346K |
| 毛利 | 115M+18% | 106M+14% | 102M+28% | 103M+40% | 96.9M+38% | 93.1M+33% | 79.8M+24% | 73.7M+24% | 70.3M | 70.0M | 64.6M | 59.4M |
| 毛利率 | 99.1% | 99.6% | 97.4% | 99.5% | 98.9% | 99.1% | 99.4% | 97.7% | 99.7% | 99.7% | 99.6% | 99.4% |
| 研發費用 | 73.9M | 61.1M | 78.8M | 70.6M | 69.0M | 56.5M | 52.8M | 51.1M | 57.5M | 45.6M | 43.2M | 38.2M |
| 銷售管理費用 | 43.9M | 37.9M | 42.6M | 39.8M | 42.8M | 40.2M | 35.5M | 38.6M | 39.3M | 41.4M | 35.5M | 35.0M |
| 營業利益 | −3.0M-80% | 7.3M-301% | −19.7M+132% | −7.2M-55% | −14.9M-44% | −3.6M-79% | −8.5M-40% | −16.0M+16% | −26.5M | −17.1M | −14.1M | −13.8M |
| 營業利益率 | -2.6% | 6.8% | -18.8% | -6.9% | -15.2% | -3.9% | -10.6% | -21.2% | -37.6% | -24.3% | -21.8% | -23.0% |
| 稅後淨利 | −808K-92% | 13.0M+158% | −30.1M-444% | −177K-98% | −10.3M-58% | 5.0M-125% | 8.7M+864% | −11.6M-32% | −24.4M | −19.7M | 906K | −17.0M |
| 淨利率 | -0.7% | 12.2% | -28.8% | -0.2% | -10.5% | 5.4% | 10.9% | -15.4% | -34.7% | -28.1% | 1.4% | -28.5% |
| 稀釋 EPS | -0.02-90% | 0.25+150% | -0.61-459% | 0.00-100% | -0.20-59% | 0.10-125% | 0.17+750% | -0.23-34% | -0.49 | -0.40 | 0.02 | -0.35 |
| 稀釋股數 | 51.0M | 52.9M | 50.3M | 50.4M | 50.3M | 51.9M | 52.8M | 50.0M | 49.9M | 48.9M | 54.2M | 48.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 485M | 453M | 468M | 498M | 488M | 477M | 538M | 505M | 833M | 443M | 444M | 432M |
| 應收帳款 | – | – | – | – | – | – | 63.7M | 60.2M | 57.8M | 52.1M | – | – |
| 存貨 | 7.8M | 8.3M | 6.7M | 5.7M | 5.5M | 6.8M | 4.5M | 3.5M | 4.2M | 4.5M | – | – |
| 總資產 | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.0B | 1.1B | 1.0B | 994M | 597M | – | – |
| 有息負債 | – | – | – | – | – | – | 439M | 453M | 453M | – | – | – |
| 總負債 | 700M | 678M | 686M | 706M | 694M | 650M | 707M | 664M | 634M | 228M | – | – |
| 股東權益 | 420M | 394M | 381M | 397M | 388M | 378M | 378M | 359M | 360M | 369M | 356M | 351M |
| 負債比 | 62.5% | 63.3% | 64.3% | 64.0% | 64.1% | 63.2% | 65.2% | 64.9% | 63.8% | 38.2% | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | 99.1M | 52.5M | 380M | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −13.8M-3267% | – | – | – | 435K | – | – | −4.6M | – | – | – |
| 資本支出 | – | 1.8M | – | – | – | 298K | – | – | 430K | – | – | – |
| 自由現金流 | – | −15.6M-11455% | – | – | – | 137K | – | – | −5.0M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -14.6% | – | – | – | 0.1% | – | – | -7.1% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 400M
| Reportable | 400M | 100.0% | +29.0% |
|---|
產品／服務2025 年度 · 400M
| Sale Of Therapies | 400M | 100.0% | +29.0% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 400M | +29.0% | −35.5M | -8.9% | -0.71 | −15.1M |
| FY2024 | 310M | +24.4% | −51.1M | -16.5% | -1.02 | 20.9M |
| FY2023 | 249M | +43.1% | −55.3M | -22.2% | -1.13 | −2.5M |
| FY2022 | 174M | +4175.6% | −52.5M | -30.1% | -1.15 | −51.4M |
| FY2021 | 4.1M | – | −180M | -4,414.6% | -4.24 | −144M |